Department of Endocrinology & Metabolism, All India Institute of Medical Sciences, New Delhi, India.
Department of Endocrinology & Metabolism, All India Institute of Medical Sciences, New Delhi, India.
Diabetes Metab Syndr. 2024 Jun;18(6):103064. doi: 10.1016/j.dsx.2024.103064. Epub 2024 Jun 20.
To evaluate burden of postpartum diabetes and other cardiometabolic risk factors among women who test positive for gestational diabetes mellitus (GDM) by International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria, but negative by alternate criteria.
This prospective cross-sectional study was conducted from 2019 to 2022 and is a sub-study of the CHIP-F cohort (Cohort Study of Indian Women with Hyperglycemia in Pregnancy and their Families).
Study participants (n = 826; 183 with normoglycemia and 643 with GDM using IADPSG criteria) were evaluated at a median (IQR) postpartum interval of 31 (21-45) months. Using the United Kingdom National Institute of Health and Care Excellence (UK NICE), Canadian Diabetes Association (CDA), and Diabetes in Pregnancy Study Group India (DIPSI) criteria, 251 (39.0 %), 148 (23.0 %) and 384 (59.7 %) women who tested positive for GDM by IADPSG criteria, would have tested negative. The incidence of postpartum diabetes among such women was 30.4, 34.3, and 48.2 per 1000 women-years, respectively, which was significantly higher than those testing negative by both IADPSG and UK NICE (5.0 per 1000 women-years), IADPSG and CDA (9.2/1000 women-years) and IADPSG and DIPSI criteria (5.0/1000 women-years). The burden of obesity and metabolic syndrome was also significantly higher in such women.
We found a significant burden of postpartum diabetes and cardiometabolic risk factors among women who tested positive for GDM by IADPSG, but negative by alternate criteria. There are potential clinical implications of a "failed" diagnosis for future cardiometabolic diseases that need to be carefully examined.
评估通过国际妊娠合并糖尿病研究组织(IADPSG)标准诊断为妊娠期糖尿病(GDM)阳性但通过其他标准诊断为阴性的女性的产后糖尿病及其他心血管代谢危险因素的负担。
本前瞻性横断面研究于 2019 年至 2022 年进行,是 CHIP-F 队列(妊娠合并高血糖的印度女性及其家庭的队列研究)的子研究。
研究参与者(n=826;183 例血糖正常和 643 例 IADPSG 标准诊断为 GDM)在产后中位数(IQR)间隔 31(21-45)个月进行评估。使用英国国家卫生与保健卓越研究所(NICE)、加拿大糖尿病协会(CDA)和印度妊娠糖尿病研究组(DIPSI)标准,251(39.0%)、148(23.0%)和 384(59.7%)例通过 IADPSG 标准诊断为 GDM 阳性的女性将被诊断为阴性。这些女性的产后糖尿病发病率分别为每 1000 名女性 30.4、34.3 和 48.2 例,显著高于同时通过 IADPSG 和 NICE(每 1000 名女性 5.0 例)、IADPSG 和 CDA(每 1000 名女性 9.2 例)和 IADPSG 和 DIPSI 标准(每 1000 名女性 5.0 例)诊断为阴性的女性。这些女性的肥胖和代谢综合征的负担也明显更高。
我们发现,通过 IADPSG 标准诊断为 GDM 阳性但通过其他标准诊断为阴性的女性存在显著的产后糖尿病和心血管代谢危险因素负担。对于未来的心血管代谢疾病,这种“失败”诊断存在潜在的临床意义,需要仔细研究。